OLK / Olink Holding AB (publ) - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Olink Holding AB (publ) - Depositary Receipt (Common Stock)
US ˙ NasdaqGM ˙ US6807101000
HINDI NA ACTIVE ANG SIMBONG ITO

Mga Batayang Estadistika
LEI 8945004Z7ZHV3LML4J27
CIK 1835539
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Olink Holding AB (publ) - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
July 22, 2024 15F-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact name of registrant as specified in

July 22, 2024 EX-99.1

Uppsala, in July 2024 Olink Holding AB (publ) The Board of Directors

Exhibit 99.1 To the shareholders of Olink Holding AB (publ) Orion Acquisition AB (the "Majority Shareholder") owns in total more than nine-tenths of the shares in Olink Holding AB (publ) (reg. no. 559189-7755) ("Olink"). According to Chapter 22, Section 1 of the Swedish Companies Act (2005:551), the Majority Shareholder is therefore entitled to redeem the remaining shares from the other shareholde

July 22, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16A SE-753 30 Uppsala, Sweden (Address of principal execu

July 17, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

July 17, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 20) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

July 11, 2024 EX-99.1

Uppsala in July 2024 The Board of Directors Olink Holding AB (publ)

Exhibit 99.1 This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. Notice to attend the Extra General Meeting of Olink Holding AB (publ) The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.

July 11, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16A SE-753 30 Uppsala, Sweden (Address of principal execu

July 10, 2024 S-8 POS

As filed with the Securities and Exchange Commission on July 10, 2024

As filed with the Securities and Exchange Commission on July 10, 2024 Registration No.

July 10, 2024 S-8 POS

As filed with the Securities and Exchange Commission on July 10, 2024

As filed with the Securities and Exchange Commission on July 10, 2024 Registration No.

July 10, 2024 EX-99.(A)(5)(W)

Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024

Exhibit (a)(5)(W) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

July 10, 2024 S-8 POS

As filed with the Securities and Exchange Commission on July 10, 2024

As filed with the Securities and Exchange Commission on July 10, 2024 Registration No.

July 10, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 19) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

July 10, 2024 POSASR

As filed with the Securities and Exchange Commission on July 10, 2024

As filed with the Securities and Exchange Commission on July 10, 2024 Registration No.

July 10, 2024 S-8 POS

As filed with the Securities and Exchange Commission on July 10, 2024

As filed with the Securities and Exchange Commission on July 10, 2024 Registration No.

July 10, 2024 EX-99.(A)(5)(X)

Dear Shareholders and Market Participants,

Exhibit (a)(5)(X) Dear Shareholders and Market Participants, Thermo Fisher Scientific has today announced the commencement of a subsequent offering period in order to allow any remaining shareholders accept the offer for the common shares of Olink.

July 10, 2024 EX-99.(A)(5)(T)

Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024

Exhibit (a)(5)(T) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

July 10, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16A SE-753 30 Uppsala, Sweden (Address of principal execu

July 10, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

July 10, 2024 EX-99.(A)(1)(I)

Cash consideration

Exhibit (a)(1)(I) Acceptance Form for the Subsequent Offering Period by Orion Acquisition AB to shareholders in Olink Holding AB (publ) Shareholders of Common Shares, ISIN: SE0015797568 Please submit this Acceptance form to: DNB Markets, a part of DNB Bank ASA, Sweden Branch Regeringsgatan 59, 105 88 Stockholm, Sweden DNB Markets, Securities Services at emissioner@dnb.

July 8, 2024 EX-99.(A)(5)(S)

Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

Exhibit (a)(5)(S) Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher Uppsala, Sweden, July 8, 2024 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc.

July 8, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

July 5, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

July 5, 2024 EX-99.1

Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024

Exhibit 99.1 Press release 5 July 2024 Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024 At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755 (the “Company”), the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the

July 5, 2024 EX-99.(E)(29)

1

Exhibit (e)(29) CONTRACT OF EMPLOYMENT CONTRACT DATE: July 1st 2024 BETWEEN: 1. OLINK PROTEOMICS LIMITED of 24 Old Queen Street, London, SW1H 9HP, United Kingdom ("the Company") 2. LINDA RAMIREZ-EAVES of 33 Marlborough Road, Richmond, TW10 6JT, United Kingdom (“the Employee”) It is agreed that the Company will employ you upon and subject to the following terms and conditions. For the avoidance of

July 5, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16F SE-75330 Uppsala, Sweden (Address of principal execut

June 20, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

June 20, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 18) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

June 20, 2024 EX-99.(A)(5)(V)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on July 9, 2024

Exhibit (a)(5)(V) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

June 11, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16F SE-75330 Uppsala, Sweden (Address of principal execut

June 11, 2024 EX-99.1

This is a translation of the Swedish original. In case of any discrepancies between this translation and the

Exhibit 99.1 This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. Notice to attend the Extra General Meeting of Olink Holding AB (publ) The shareholders of Olink Holding AB (publ) (the “Company”), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.

May 14, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 17) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

May 14, 2024 EX-99.(A)(5)(U)

* * *

Exhibit (a)(5)(U) The following is an excerpt from the transcript of Thermo Fisher’s CEO remarks given on May 14, 2024 at the Bank of America Securities 2024 Health Care Conference: [W]e're looking forward first to finishing the regulatory process in Olink, and we're on track for the middle of the year. . . . I'm just excited to welcome the colleagues and have that offering for our customers. * * *

May 13, 2024 EX-99.1

Olink reports first quarter 2024 financial results

Exhibit 99.1 Olink reports first quarter 2024 financial results UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights •First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant cur

May 13, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-402

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16A SE-753 30 Uppsala, Sweden (Address of principal execut

May 13, 2024 EX-99.2

Three months ended March 31,

Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended March 31, Amounts in thousands of U.S. Dollars Note 2024 2023 Revenue 4 $ 28,751 $ 27,457 Cost of revenue (11,306) (9,843) Gross profit 17,445 17,614 Selling expenses (13,903) (11,995) Administrative expenses (19,459) (16,381) Research and development expenses (10,459) (6,

May 1, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota v

May 1, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 16) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

May 1, 2024 EX-99.(A)(5)(Q)

Olink Tender Offer Extension Employee Letter from Olink CEO

Exhibit (a)(5)(Q) Olink Tender Offer Extension Employee Letter from Olink CEO May 1, 2024 Dear Colleagues, I would like to update you on recent developments in our agreement to combine with Thermo Fisher Scientific.

May 1, 2024 EX-99.(A)(5)(T)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on June 18, 2024

Exhibit (a)(5)(T) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

April 24, 2024 EX-99.(A)(5)(S)

* * *

Exhibit (a)(5)(S) The following is an excerpt from the transcript of Thermo Fisher’s First Quarter Earnings Call held on April 24, 2024: Turning to our planned acquisition of Olink, we’re working through the regulatory process and the transaction is on track to close by mid-2024. We look forward to welcoming our new colleagues to the company later this year. * * *

April 24, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 15) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

April 19, 2024 EX-FILING FEES

Calculation of Filing Fee Table (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, quota value approx.

April 19, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagatan 16F SE-75330 Uppsala, Sweden (Address of principal execu

April 19, 2024 S-8

As filed with the Securities and Exchange Commission on April 19, 2024

As filed with the Securities and Exchange Commission on April 19, 2024 Registration No.

April 19, 2024 EX-99.1

Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

Exhibit 99.1 Press release 19 April 2024 Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024 At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the no

April 19, 2024 EX-99.3

Second Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan

Exhibit 99.3 Second Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan This Second Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan (this “Second Amendment”), made as of 14 March 2024, is made and adopted by Olink Holding AB (publ), a Swedish public limited liability company (the “Company”). Capitalized terms used but not otherwis

March 25, 2024 EX-15.1

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: •Registration Statement (Form S-8 No. 333-254844) •Registration Statement (Form S-8 No. 333-264181) •Registration Statement (Form F-3 No. 333-269285) •Registration Statement (Form S-8 No. 333-271290) of our reports dated March 25, 2024, with r

March 25, 2024 EX-4.7

limitation failure to properly perform routine maintenance and maintain the Instrument site in accordance with Fluidigm’s requirements or the use of the Product with any non- Fluidigm product (except as they may be specifically validated by Olink or

limitation failure to properly perform routine maintenance and maintain the Instrument site in accordance with Fluidigm’s requirements or the use of the Product with any non- Fluidigm product (except as they may be specifically validated by Olink or Fluidigm, with respect to standard laboratory reagents, consumables, tools and equipment ancillary to use of the Product), (ii) has been repaired, alt

March 25, 2024 EX-4.9

DocuSign Envelope ID: 55E92D28-CE56-49DA-97CC-5D28F616C5BE AMENDMENT NO. 7 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 7 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its prin

DocuSign Envelope ID: 55E92D28-CE56-49DA-97CC-5D28F616C5BE AMENDMENT NO. 7 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 7 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Standard BioTools Inc. (formerly known as Fluidigm Corpo

March 25, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal exec

March 25, 2024 EX-4.6

AMENDMENT NO. 4 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 4 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752

AMENDMENT NO. 4 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 4 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Fluidigm Corporation, a Delaware corporation organized and existing under the laws of the United States of America,

March 25, 2024 EX-4.13

DocuSign Envelope ID: B594FC2C-FC13-46EB-9861-E582CB82E09B First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan This First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan (this

DocuSign Envelope ID: B594FC2C-FC13-46EB-9861-E582CB82E09B First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan This First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan (this “First Amendment”), made as of 14 March 2023, is made and adopted by Olink Holding AB (publ), a Swedish public limited liability company (the “Company”).

March 25, 2024 EX-13.2

Certification by the Principal Financial Officer pursuant to

Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report on Form 20-F of Olink Holding AB (publ) (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Oskar

March 25, 2024 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

March 25, 2024 EX-99.3

Olink publishes 2023 annual report

Exhibit 99.3 Olink publishes 2023 annual report UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/. About Olink Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific communit

March 25, 2024 EX-4.10

DocuSign Envelope ID: 530C9DF2-3B27-4865-9BFB-8BDC2388C913 AMENDMENT NO. 8 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 8 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its prin

DocuSign Envelope ID: 530C9DF2-3B27-4865-9BFB-8BDC2388C913 AMENDMENT NO. 8 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 8 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjölds vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Standard BioTools Inc. (formerly known as Fluidigm Corp

March 25, 2024 EX-15.3

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-269285) and Form S 8 (Nos.333-271290, 333-264181 and 333-254844) of Olink Holding AB (publ) of our report dated March 17, 2022 relating to the financial statements, which appears in this Form 20-F. /s/ Öhrlings Pricewaterhouse

March 25, 2024 EX-99.1

Olink reports fourth quarter and full year 2023 financial results

Exhibit 99.1 Olink reports fourth quarter and full year 2023 financial results UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights •Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis a

March 25, 2024 EX-12.2

Certification by the Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Oskar Hjelm, certify that: 1.I have reviewed this annual report on Form 20-F of Olink Holding AB (publ) (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a

March 25, 2024 EX-2.5

Description of Securities DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION

Exhibit 2.5 Description of Securities DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Introduction Set forth below is a summary of certain information concerning Olink Holding AB (publ)'s (“us,” “our,” “we” or the “Company”) share capital as well as a description of certain provisions of our articles of association and relevant provisions of the Swedish Companies Act (Sw. Aktiebolagslagen

March 25, 2024 EX-99.2

The Board of Directors and the CEO of Olink Holding AB (publ) Corporate identity number 559189-7755 submit the following Annual report and consolidated financial statements for the financial year 1 January – 31 December 2023

Exhibit 99.2 The Board of Directors and the CEO of Olink Holding AB (publ) Corporate identity number 559189-7755 submit the following Annual report and consolidated financial statements for the financial year 1 January – 31 December 2023 Olink Holding AB (publ) 559189-7755 Financial statements Directors’ report 2 Consolidated statement of income and other comprehensive income for the year ended De

March 25, 2024 EX-97

www.olink.com Olink Proteomics, Dag Hammarskjölds väg 52B Uppsala Science Park, SE-751 83 Uppsala, Sweden Phone: +46 (0)18 444 39 70, [email protected], Reg no: 559046-8632 1 Executive Officer Incentive Compensation Recovery Policy Document Owner Docume

www.olink.com Olink Proteomics, Dag Hammarskjölds väg 52B Uppsala Science Park, SE-751 83 Uppsala, Sweden Phone: +46 (0)18 444 39 70, [email protected], Reg no: 559046-8632 1 Executive Officer Incentive Compensation Recovery Policy Document Owner Document Holder Remuneration Committee General Counsel Approval Board of Directors of Olink Holding AB (publ) (the “Company” and together with its subsidiar

March 25, 2024 EX-13.1

Certification by the Principal Executive Officer pursuant to

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report on Form 20-F of Olink Holding AB (publ) (the “Company”) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Jon He

March 25, 2024 EX-12.1

Certification by the Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jon Heimer, certify that: 1.I have reviewed this annual report on Form 20-F of Olink Holding AB (publ) (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a

March 25, 2024 EX-4.8

DocuSign Envelope ID: 9E9E7F5C-C117-4B88-AA76-E4E4C42223EE AMENDMENT NO. 6 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 6 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its prin

DocuSign Envelope ID: 9E9E7F5C-C117-4B88-AA76-E4E4C42223EE AMENDMENT NO. 6 TO OEM SUPPLY & DEVELOPMENT AGREEMENT Amendment No. 6 to OEM Supply & Development Agreement (the "Amendment"), between Olink Proteomics AB, a Swedish corporation with its principal place of business at Dag Hammarskjöld vag 52B, SE-752 37 Uppsala, Sweden ("Olink"), and Standard BioTools Inc. (formerly known as Fluidigm Corpo

March 15, 2024 EX-99.1

Uppsala in March 2024 The Board of Directors Olink Holding AB (publ)

Exhibit 99.1 This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. Notice to attend the Annual General Meeting of Olink Holding AB (publ) UPPSALA, Sweden, March 15, 2024 - The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend t

March 15, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal exec

March 6, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal exec

March 6, 2024 EX-99.(A)(5)(R)

I’m very excited about Olink. We’re working through the regulatory process. And when I think about that, we’re on target. We’re on track to close that the middle of the year. I cannot wait to welcome our new colleagues from Olink, just a spectacular

Exhibit (a)(5)(R) The following is an excerpt from the transcript of Thermo Fisher’s CEO remarks given on March 6, 2024 at the TD Cowen 44th Annual Health Care Conference: I’m very excited about Olink.

March 6, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 14) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

March 1, 2024 EX-99.(A)(5)(Q)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on April 30, 2024

Exhibit (a)(5)(Q) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

March 1, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 13) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

March 1, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

February 20, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

February 20, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 12) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

January 31, 2024 EX-99.(A)(5)(P)

[. . .] * * *

Exhibit (a)(5)(P) The following is an excerpt from the transcript of Thermo Fisher’s Fourth Quarter and Full Year 2023 earnings call held on January 31, 2024: During the fourth quarter, we announced our intent to acquire Olink, a provider of advanced proteomics solutions that help researchers to gain an understanding of disease at the protein level rapidly and efficiently.

January 31, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 11) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

January 18, 2024 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal ex

January 4, 2024 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 10) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

January 4, 2024 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

January 4, 2024 EX-99.(A)(5)(O)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on February 29, 2024

Exhibit (a)(5)(O) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

December 22, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 9) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

December 22, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

December 15, 2023 EX-99.(A)(5)(N)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on January 3, 2024

Exhibit (a)(5)(N) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

December 15, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

December 15, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 8) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

December 15, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

December 14, 2023 CORRESP

***

December 14, 2023 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers and Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Christina Chalk, Shane Callaghan and Eddie Kim Re: Olink Holding AB (publ) Schedule 14D-9 Filed October 31, 2023 File No. 005-93360 Ladies and Gentlemen: This letter sets forth the response of Olink Holding AB (p

December 12, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 7) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

December 5, 2023 EX-99.(A)(5)(B)

Goldman Sachs Bank Europe SE, Sweden Bankfilial

Exhibit (a)(5)(B) Goldman Sachs Bank Europe SE, Sweden Bankfilial Blasieholmsgatan 7 1111 48 Stockholm I Sweden Tel: +46 (0)8 407 4900 PERSONAL AND CONFIDENTIAL October 17, 2023 Board of Directors Olink Holding AB (publ) Uppsala Science Park SE-751 83 Uppsala Sweden Ladies and Gentlemen: You have requested our opinion as to the fairness from a financial point of view to the holders (other than Thermo Fisher Scientific Inc.

December 5, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

December 4, 2023 CORRESP

***

December 4, 2023 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Application and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Al Pavot and Jeanne Baker Re: Olink Holding AB (publ) Schedule 14D-9 Filed October 31, 2023 File No. 005-93360 Ladies and Gentlemen: This letter sets forth the response of Olink Holding AB (publ) (the “

December 1, 2023 EX-99.(A)(1)(H)

AMENDED AND RESTATED OFFER TO PURCHASE FOR CASH All Outstanding Common Shares All Outstanding American Depositary Shares, each representing one Common Share,

TABLE OF CONTENTS Exhibit (a)(1)(H) AMENDED AND RESTATED OFFER TO PURCHASE FOR CASH   All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, of   Olink Holding AB (publ) at $26.

December 1, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 5) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 5)   Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer))   ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of   THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Sh

December 1, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 6) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

December 1, 2023 EX-99.(A)(5)(M)

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on December 14, 2023

Exhibit (a)(5)(M) FOR IMMEDIATE RELEASE Media Contact Information: Sandy Pound Investor Contact Information: Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

November 15, 2023 EX-99.2

Three months ended September 30,

Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended September 30, Nine months ended September 30, Amounts in thousands of U.S. Dollars Note 2023 2022 2023 2022 Revenue 4 $ 44,152 $ 31,772 $ 101,045 $ 81,963 Cost of goods sold (13,265) (10,785) (35,253) (30,589) Gross profit 30,887 20,987 65,792 51,374 Selling expenses (14,2

November 15, 2023 EX-99.1

Olink reports third quarter 2023 financial results

Exhibit 99.1 Olink reports third quarter 2023 financial results UPPSALA, Sweden, November 15, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023. Highlights •Third quarter 2023 revenue totaled $44.2 million, representing year over year growth of 39% on a reported basis and 38% on a c

November 15, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal e

November 14, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

November 14, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

November 13, 2023 EX-99.(A)(5)(K)

Message to Current and Former Employees with Global Share Accounts:

Exhibit (a)(5)(K) Message to Current and Former Employees with Global Share Accounts: Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc.

November 13, 2023 EX-99.(A)(5)(I)

Olink Holding AB (publ) Employee Frequently Asked Questions

Exhibit (a)(5)(I) Olink Holding AB (publ) Employee Frequently Asked Questions 1. What is the tender offer? The “tender offer” is a public bid for shareholders of Olink Holding AB (publ) (“Olink”) to sell their Olink common shares (“Common Shares”) and American Depositary Shares (which each represent one Common Share) (“ADSs”), to Thermo Fisher Scientific Inc., a Delaware corporation (“Thermo Fishe

November 13, 2023 SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Olink Holding AB (publ) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

November 13, 2023 EX-99.(A)(5)(L)

Email to Current and Former Employees with Global Share Accounts:

Exhibit (a)(5)(L) Email to Current and Former Employees with Global Share Accounts: Orion Acquisition AB (“Buyer”), a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc.

November 13, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

November 6, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

November 6, 2023 EX-99.(A)(5)(J)

Dear nominees and other market participants holding Olink Holding AB (publ) common shares, ISIN SE0015797568

Exhibit (a)(5)(J) Dear nominees and other market participants holding Olink Holding AB (publ) common shares, ISIN SE0015797568 Reference is made to the previously announced tender offer (the “Offer”) by Orion Acquisition AB for all the outstanding common shares and ADSs of Olink Holding AB (publ), which was commenced on October 31, 2023.

November 2, 2023 SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) ORION ACQUISITION AB (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common Shares,

November 2, 2023 EX-99.(A)(5)(I)

Aktuella Transaktioner Public Tender Offer to Shareholders in Olink Holding AB (publ) ThermoFisher-medhvitt Thermo Fisher Scientific commenced on October 31, 2023 a Tender Offer for all shares in Olink Holding AB (publ). DNB Markets has been appointe

Exhibit (a)(5)(I) Aktuella Transaktioner Public Tender Offer to Shareholders in Olink Holding AB (publ) ThermoFisher-medhvitt Thermo Fisher Scientific commenced on October 31, 2023 a Tender Offer for all shares in Olink Holding AB (publ).

October 31, 2023 EX-99.(A)(5)(A)

-2-

Exhibit (a)(5)(A) October 17, 2023 The Board of Directors Olink Holding AB (publ) Uppsala Science Park SE-751 83 Uppsala Sweden Members of the Board of Directors: You have requested our opinion as to the fairness, from a financial point of view, to the holders of common shares, quota value SEK 2.

October 31, 2023 EX-99.(E)(14)

Employment Contract

Exhibit (e)(14) Employment Contract Olink Proteomics AB 559046-8632 Uppsala (the “Company”) and Elias Berglund the “Employee”) have today entered into the following agreement regarding an employment at the Company.

October 31, 2023 EX-99.(D)(5)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(5) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(E)(16)

OLINK HOLDING AB (publ) AMENDED AND RESTATED 2021 INCENTIVE AWARD PLAN 2023 INTERNATIONAL RESTRICTED STOCK UNIT AWARD GRANT NOTICE

Exhibit (e)(16) OLINK HOLDING AB (publ) AMENDED AND RESTATED 2021 INCENTIVE AWARD PLAN 2023 INTERNATIONAL RESTRICTED STOCK UNIT AWARD GRANT NOTICE Olink Holding AB (publ), a Swedish public limited liability company (the “Company”), pursuant to its Amended and Restated 2021 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restricted Stock Units” or “RSUs”) in accordance with the percentage of the Participant’s base salary as notified to the Participant in the Equity section of the Company’s Bob HR system, at a per-unit price equal to the public price for one of the Company’s ADRs at market close on April 6, 2023.

October 31, 2023 EX-99.(E)(15)

INDEFINITE-TERM EMPLOYMENT CONTRACT

Exhibit (e)(15) INDEFINITE-TERM EMPLOYMENT CONTRACT CONTRAT DE TRAVAIL A DUREE INDETERMINEE BETWEEN THE UNDERSIGNED : ENTRE : ⮚ Olink Proteomics SAS, Single-member simplified joint stock company with the SIREN number 919 080 143, Having its registered office at 9 rue du 4 septembre – 75002 Paris (France), ⮚ Olink Proteomics SAS, Société par actions simplifiée unipersonnelle dont le numéro SIREN est le 919 080 143, Ayant son siège social 9 rue du 4 septembre –75002 Paris (France), ⮚ Represented for the purpose hereof by Oskar Hjelm, President Représentée par M Oskar Hjelm.

October 31, 2023 EX-99.(E)(13)

Employment Contract

Exhibit (e)(13) Employment Contract Olink Proteomics AB 559046-8632 Uppsala (the “Company”) and Anna Marsell (the “Employee”) have today entered into the following agreement regarding an employment at the Company.

October 31, 2023 EX-99.(D)(6)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(6)     CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(D)(11)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(11) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(A)(5)(B)

Goldman Sachs Bank Europe SE, Sweden Bankfilial

Exhibit (a)(5)(B) Goldman Sachs Bank Europe SE, Sweden Bankfilial Blasieholmsgatan 7 I 111 48 Stockholm I Sweden Tel: +46 (0)8 407 4900 PERSONAL AND CONFIDENTIAL October 17, 2023 Board of Directors Clink Holding AB (publ) Uppsala Science Park SE-751 83 Uppsala Sweden Ladies and Gentlemen: Attached is our opinion letter, dated October 17, 2023 ("Opinion Letter''),with respect to the fairness from a financial point of view to the holders (other than Thermo Fisher Scientific Inc.

October 31, 2023 EX-99.(A)(1)(A)

OFFER TO PURCHASE FOR CASH All Outstanding Common Shares All Outstanding American Depositary Shares, each representing one Common Share,

TABLE OF CONTENTS Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH   All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, of   Olink Holding AB (publ) at $26.

October 31, 2023 EX-99.(A)(1)(G)

Notice of Offer to Purchase All Outstanding Common Shares and All Outstanding American Depositary Shares, each representing one Common Share, OLINK HOLDING AB (PUBL) $26.00 per Share or ADS, pursuant to the Offer to Purchase, dated October 31, 2023,

Exhibit (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Offer Securities (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

October 31, 2023 EX-99.(A)(1)(D)

OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 GOLDCUP 33985 AB (u.c.t. Orio

Exhibit (a)(1)(D) OFFER TO PURCHASE FOR CASH   ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE   OF OLINK HOLDING AB (publ)   PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023   BY GOLDCUP 33985 AB (u.

October 31, 2023 EX-99.(D)(7)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(7) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(D)(4)

June 25, 2023

Exhibit (d)(4) June 25, 2023 CONFIDENTIAL Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451 Ladies and Gentlemen: In connection with proposed discussions between Olink Holding AB (publ) (the “Company”) and Thermo Fisher Scientific Inc. regarding a Company business update (such discussions, the “Business Update”) or the potential consideration by Thermo Fisher Scientific I

October 31, 2023 EX-99.(D)(3)

TRANSFER RESTRICTION AGREEMENT

Exhibit (d)(3) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(A)(5)(H)

Olink Tender Offer Launch Employee Letter from Olink CEO

Exhibit (a)(5)(H) Olink Tender Offer Launch Employee Letter from Olink CEO Dear Colleagues, I am writing to share an update on the next step in our agreement to combine with Thermo Fisher Scientific.

October 31, 2023 EX-99.(E)(17)

OLINK HOLDING AB (publ) 2021 INCENTIVE AWARD PLAN 2023 INTERNATIONAL STOCK OPTION GRANT NOTICE

Exhibit (e)(17) OLINK HOLDING AB (publ) 2021 INCENTIVE AWARD PLAN 2023 INTERNATIONAL STOCK OPTION GRANT NOTICE Olink Holding AB (publ), a Swedish public limited liability company (the “Company”), pursuant to its 2021 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option (“Option”) to purchase such number of Shares (as defined in the Plan) as set forth below.

October 31, 2023 EX-99.(A)(5)(H)

Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink Shareholders to Receive $26.00 per Common Share and ADS in Cash

Exhibit (a)(5)(H)   FOR IMMEDIATE RELEASE Media Contact Information: Investor Contact Information: Sandy Pound Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: sandy.

October 31, 2023 EX-99.(E)(11)

Anställningsavtal

Exhibit (e)(11) Sidan 1 av 5 Anställningsavtal Mellan Olink Proteomics AB 559046–8632 Uppsala (nedan kallat ”Bolaget”) och Ida Grundberg (nedan kallad den ”Anställde”) har denna dag träffats följande villkor för anställning i bolaget.

October 31, 2023 EX-99.(D)(10)

RETENTION BONUS AGREEMENT

Exhibit (d)(10) RETENTION BONUS AGREEMENT This Retention Bonus Agreement (“Agreement”) is made and entered into as of October   , 2023, by and between Thermo Fisher Scientific, Inc.

October 31, 2023 EX-99.(A)(1)(F)

Stockholm, 31 October 2023

Exhibit (a)(1)(F)     Stockholm, 31 October 2023 Dear Shareholders, nominee banks and other market participants holding shares in Olink Holding AB (publ) (“Olink”), Thermo Fisher Scientific Inc.

October 31, 2023 EX-99.(A)(1)(C)

Cash consideration

Exhibit (a)(1)(C)     Acceptance Form for the public cash tender offer by Goldcup 33985 AB (u.

October 31, 2023 EX-99.(E)(8)

Olink Holding AB, reg. no 559189-7755, Uppsala (the "Company") and Jon Heimer, personal identity number, Stockholm, (the "Executive"), have today concluded the following

EX-99.(E)(8) 5 tm2328635d3ex99-e8.htm EXHIBIT (E)(8) Exhibit (e)(8) Olink Holding AB, reg. no 559189-7755, Uppsala (the "Company") and Jon Heimer, personal identity number, Stockholm, (the "Executive"), have today concluded the following EXECUTIVE AGREEMENT 1. Position and Start Date 1.1 The Executive is hereby employed as Chief Executive Officer/President (CEO) of the Company. This Agreement is e

October 31, 2023 EX-99.(E)(12)

Key Employee Agreement

Exhibit (e)(12) June 24, 2020 Carl Raimond Re: Offer of Employment Dear Carl: On behalf of Clink Proteomics, Inc.

October 31, 2023 EX-99.(D)(8)

HIGHLIGHTED EXECUTIVE BENEFITS

Exhibit (d)(8)     Mr. Carl Raimond   Dear Carl Raimond, We are very excited about you joining Thermo Fisher Scientific Inc. following the expected consummation of our acquisition of Olink. This letter is intended to clarify provisions of your employment with us that will only become effective as of the date Olink becomes a wholly-owned subsidiary of Thermo Fisher Scientific Inc., or such earlier

October 31, 2023 EX-99.(D)(12)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(12) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(D)(1)

PURCHASE AGREEMENT THERMO FISHER SCIENTIFIC INC. OLINK HOLDING AB (PUBL), dated as of October 17, 2023

TABLE OF CONTENTS Exhibit (d)(1) PURCHASE AGREEMENT   between   THERMO FISHER SCIENTIFIC INC.

October 31, 2023 SC 14D9

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Olink Holding AB (publ) (Name of Subject Company

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota va

October 31, 2023 EX-FILING FEES

Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (u.c.t. Orion Acquisition AB) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Parent of Offeror

Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (u.

October 31, 2023 EX-99.(D)(13)

CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED.

Exhibit (d)(13) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 31, 2023 EX-99.(A)(1)(B)

Letter of Transmittal to Tender American Depositary Shares (“ADSs”) (Each Representing 1 Common Share) of OLINK HOLDING AB (PUBL) $26.00 per ADS, in cash, without interest, pursuant to the Offer to Purchase, dated October 31, 2023 GOLDCUP 33985 AB (u

Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

October 31, 2023 EX-99.(E)(18)

OLINK HOLDING AB (publ) 2021 INCENTIVE AWARD PLAN 2023 U.S. STOCK OPTION GRANT NOTICE

Exhibit (e)(18) OLINK HOLDING AB (publ) 2021 INCENTIVE AWARD PLAN 2023 U.S. STOCK OPTION GRANT NOTICE Olink Holding AB (publ), a Swedish public limited liability company (the “Company”), pursuant to its 2021 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option (“Option”) to purchase such number of Shares (as def

October 31, 2023 EX-99.(A)(1)(E)

OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE OLINK HOLDING AB (publ) PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023 GOLDCUP 33985 AB (u.c.t. Orio

Exhibit (a)(1)(E) OFFER TO PURCHASE FOR CASH ALL OUTSTANDING COMMON SHARES AND ALL OUTSTANDING AMERICAN DEPOSITARY SHARES, EACH REPRESENTING ONE COMMON SHARE   OF   OLINK HOLDING AB (publ)   PURSUANT TO THE OFFER TO PURCHASE DATED OCTOBER 31, 2023   BY   GOLDCUP 33985 AB (u.

October 31, 2023 SC TO-T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) GOLDCUP 33985 AB (U.C.T. ORION ACQUISITION AB) (Offeror) a direct, wholly owned subsidiary of THERMO FISHER SCIENTIFIC INC. (Ultimate Parent of Offeror) Common

October 31, 2023 EX-99.(E)(9)

Anställningsavtal

Exhibit (e)(9) Oskar Hjelm Confirmation of new compensation This letter is to confirm the changes to your employment with Olink Proteomics AB effective 1 April 2021 New Salary: 215 000 SEK per month Bonus 50% of your base salary All other employment conditions will stay the same.

October 31, 2023 EX-99.(E)(10)

Employment Contract

EX-99.(E)(10) 7 tm2328635d3ex99-e10.htm EXHIBIT (E)(10) Exhibit (e)(10) Employment Contract Olink Proteomics AB 559046-8632 Uppsala (the "Company") and Rickard El Tarzi (the "Employee") have today entered into the following agreement regarding an employment at the Company. PERSONAL INFORMATION Name: Rickard El Tarzi Personal id #: The Company and the Employee are referred to individually as "Party

October 31, 2023 EX-99.(D)(9)

NONCOMPETITION AGREEMENT

Exhibit (d)(9) NONCOMPETITION AGREEMENT THIS AGREEMENT, dated as of October 15, 2023, is made by and between Carl Raimond (the “Employee”), and Thermo Fisher Scientific Inc.

October 31, 2023 EX-99.(D)(2)

TENDER AND SUPPORT AGREEMENT

Exhibit (d)(2) CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT, BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

October 25, 2023 SC TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) American Depositary Shares, each representing one Common Share, quota value SEK 2.

October 25, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal ex

October 25, 2023 EX-99.1

The following is an excerpt from the transcript of Thermo Fisher’s Q3 2023 earnings call held on October 25, 2023

Exhibit 99.1 The following is an excerpt from the transcript of Thermo Fisher’s Q3 2023 earnings call held on October 25, 2023: Shortly after the close of the quarter we announced the agreement to acquire Olink, a company that is accelerating proteomics. Olink’s products enable leading academic researchers and the biopharmaceutical companies to gain an understanding of disease at the protein level

October 18, 2023 EX-99.1

PURCHASE AGREEMENT THERMO FISHER SCIENTIFIC INC. OLINK HOLDING AB (PUBL), dated as of October 17, 2023 TABLE OF CONTENTS

Exhibit 99.1 Execution Version PURCHASE AGREEMENT between THERMO FISHER SCIENTIFIC INC. and OLINK HOLDING AB (PUBL), dated as of October 17, 2023 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Certain Definitions 1 ARTICLE II THE OFFER 13 Section 2.1 The Offer 13 Section 2.2 Company Action 16 Section 2.3 Treatment of Equity Awards 17 Section 2.4 Further Actions 18 Section 2.5 Compulsory Red

October 18, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Salagaten 16A SE-753 30 Uppsala, Sweden (Address of principal ex

October 18, 2023 EX-99.2

TENDER AND SUPPORT AGREEMENT

Exhibit 99.2 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 17, 2023, is entered into by and among Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”), each of the individuals or entities set forth on Schedule A (each, a “Shareholder”, including Jon Hindar, chairman of the Company Board, and Nicolas Roelofs, mem

October 18, 2023 EX-99.3

TRANSFER RESTRICTION AGREEMENT

Exhibit 99.3 EXECUTION VERSION TRANSFER RESTRICTION AGREEMENT This TRANSFER RESTRICTION AGREEMENT (this “Agreement”), dated as of October 17, 2023, is entered into by and between Thermo Fisher Scientific Inc., a Delaware corporation (“Parent”) and each of the individuals or entities set forth on Schedule A (each, a “Shareholder”). All terms used but not otherwise defined in this Agreement shall ha

October 17, 2023 EX-99.4

TMO – OLK Partner / Supplier Letter

Exhibit 99.4 TMO – OLK Partner / Supplier Letter October 17, 2023 Dear Valued Partner: As an important partner to Thermo Fisher, I am pleased to share that we recently announced an agreement to acquire Olink, a leading provider of next generation proteomics solutions. This announcement marks an exciting milestone for Thermo Fisher and furthers our commitment to serving science as we fulfill our Mi

October 17, 2023 EX-99.5

TMO – OLK Customer Letter

Exhibit 99.5 TMO – OLK Customer Letter October 17, 2023 Dear Valued Customer: As an important Thermo Fisher customer, I am pleased to share that we recently announced an agreement to acquire Olink, a leading provider of next generation proteomics solutions. This announcement marks an exciting milestone for Thermo Fisher and furthers our commitment to serving science as we fulfill our Mission – ena

October 17, 2023 EX-99.3

The following communication was posted by Thermo Fisher Scientific, Inc. (the “Company”) on X (formerly Twitter) on October 17, 2023.

Exhibit 99.3 The following communication was posted by Thermo Fisher Scientific, Inc. (the “Company”) on X (formerly Twitter) on October 17, 2023. We are excited to announce that we have entered into an agreement to acquire @OlinkProteomics, a leading provider of next generation proteomics solutions. We look forward to welcoming their team to Thermo Fisher. Learn more in our Press Release: [Link t

October 17, 2023 EX-99.4

Click here to enter text.

Exhibit 99.4 Click here to enter text. OLK Partner / Supplier Letter October 17, 2023 Dear [INSERT PARTNER NAME // Valued Partner], I assume you have seen the press release. We are pleased to share that Olink has entered into an agreement to be acquired by Thermo Fisher Scientific, the world leader in serving science. This announcement marks the beginning of a new and exciting chapter for Olink. U

October 17, 2023 EX-99.1

TMO – OLK Marc Email to All TMO Employees

Exhibit 99.1 TMO – OLK Marc Email to All TMO Employees Marc N. Casper Chairman, President and Chief Executive Officer October 17, 2023 Dear Colleague: I am very pleased to share that Thermo Fisher has announced an agreement to acquire Olink, a company dedicated to accelerating proteomics. Olink is headquartered in Sweden with global operations and has approximately 600 employees. It offers leading

October 17, 2023 EX-99.2

TMO – OLK LSG Letter from Gianluca

Exhibit 99.2 TMO – OLK LSG Letter from Gianluca Gianluca Pettiti Executive Vice President October 17, 2023 Dear Colleague: I’m reaching out regarding the exciting announcement that Thermo Fisher made today about entering into an agreement to acquire Olink, a leading provider of next generation proteomics solutions. By now, you should have received an email from Marc Casper highlighting some of the

October 17, 2023 SC TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 OLINK HOLDING AB (PUBL) (Name of Subject Company (Issuer)) Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) American Depositary Shares, each representing one Common Share, quota value SEK 2.

October 17, 2023 EX-99.5

OLK Corporate Social Posts

Exhibit 99.5 OLK Corporate Social Posts X Post #1 We are excited to take an important step forward in our journey as we enter into an agreement to combine with @ThermoFisherScientific, the world leader in serving science. Learn more in our Press Release: https://bit.ly/3s3Owm2 Post #2 Today we announced an agreement to combine with @ThermoFisherScientific, the world leader in serving science. Toge

October 17, 2023 SC14D9C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Olink Holding AB (publ) (Name of Subject Company) Olink Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Olink Holding AB (publ) (Name of Subject Company) Olink Holding AB (publ) (Name of Person Filing Statement) American Depositary Shares, each representing one Common Share, quota value SEK 2.431906612623020 per sha

October 17, 2023 SC TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 THERMO FISHER SC

false000009774500000977452023-10-172023-10-170000097745us-gaap:CommonStockMember2023-10-172023-10-170000097745tmo:Zero875NotesDue2031Member2023-10-172023-10-170000097745tmo:Zero125NotesDue2025Member2023-10-172023-10-170000097745tmo:One500NotesDue2039Member2023-10-172023-10-170000097745tmo:Three650NotesDue2034Member2023-10-172023-10-170000097745tmo:Zero750NotesDue2024Member2023-10-172023-10-1700000

October 17, 2023 EX-99.2

Olink All-Employee Letter from Olink CEO

Exhibit 99.2 Olink All-Employee Letter from Olink CEO [Dear Colleagues / INSERT CUSTOMARY GREETING], Thanks to the hard work and dedication of this team, in just a few years Olink has grown rapidly from a small Uppsala-based growth company offering assays for a few hundred proteins, to a global organization advancing the field of proteomics. Today I’m excited to share that we have announced an agr

October 17, 2023 EX-99.3

OLK Customer Letter

Exhibit 99.3 OLK Customer Letter October 17, 2023 Dear [INSERT CUSTOMER NAME // Valued Customer], I am pleased to share that Olink has entered into an agreement to be acquired by Thermo Fisher Scientific, the world leader in serving science. This announcement marks the beginning of a new and exciting chapter for Olink. Thermo Fisher is a mission-driven company and delivers an unrivaled combination

October 17, 2023 EX-99.1

Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and M

Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact Information: Investor Contact Information: Sandy Pound Rafael Tejada Phone: 781-622-1223 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Website: www.thermofisher.com Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Grow

October 17, 2023 EX-99.1

Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and M

Exhibit 99.1 Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportunities WALTHAM, Mass. and UPPSAL

August 29, 2023 EX-99.1

Olink to participate in September investor events

Exhibit 99.1 Olink to participate in September investor events UPPSALA, Sweden, August 29, 2023 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: •Goldman Sachs 20th Annual European Medtech and Healthcare Services Conference Thursday, September 7th at 7:15 am ET •Morgan Stanley 21st Annual Global Healthcare

August 29, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princi

August 9, 2023 EX-99.2

Three months ended June 30,

Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended June 30, Six months ended June 30, Amounts in thousands of U.S. Dollars Note 2023 2022 2023 2022 Revenue 4 $ 29,436 $ 27,514 $ 56,893 $ 50,191 Cost of goods sold (12,145) (10,444) (21,988) (19,804) Gross profit 17,292 17,070 34,905 30,387 Selling expenses (12,608) (10,588)

August 9, 2023 EX-99.3

2Q 2023 earnings August 9, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Disclaimer This presentation contains express or implied "forward-looking statements," as defined under the

2Q 2023 earnings August 9, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Disclaimer This presentation contains express or implied "forward-looking statements," as defined under the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties.

August 9, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princi

August 9, 2023 EX-99.1

Olink reports second quarter 2023 financial results

Exhibit 99.1 Olink reports second quarter 2023 financial results UPPSALA, Sweden, August 9, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the second quarter ended June 30, 2023. Highlights •Second quarter 2023 revenue totaled $29.4 million, representing year over year growth of 7.0% on a reported basis and 7.2% on a cons

July 26, 2023 CORRESP

July 26, 2023

PRIVILEGED AND CONFIDENTIAL July 26, 2023 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Application and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Al Pavot and Jeanne Baker Re: Olink Holding AB (publ) Annual Report on Form 20-F Filed March 27, 2023 File No. 1-40277 Ladies and Gentlemen: This letter sets forth the response

July 13, 2023 EX-99.1

Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43

Exhibit 99.1 Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference UPPSALA, Sweden, July 13, 2023 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will h

July 13, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of principa

May 25, 2023 EX-99.1

Olink to participate in June investor events

Exhibit 99.1 Olink to participate in June investor events UPPSALA, Sweden, May 25, 2023 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: •William Blair 43rd Annual Growth Stock Conference Tuesday, June 6th •Goldman Sachs 44th Annual Global Healthcare Conference Wednesday, June 14th at 2:00 pm PT / 5:00 pm

May 25, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-402

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of principal

May 11, 2023 EX-99.3

1Q 2023 earnings May 11, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Exhibit 99.3 Disclaimer This presentation contains express or implied "forward-looking statements," as define

a2023q16-kdeck 1Q 2023 earnings May 11, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Exhibit 99.

May 11, 2023 EX-99.1

Olink reports first quarter 2023 financial results

Exhibit 99.1 Olink reports first quarter 2023 financial results UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023. Highlights •First quarter 2023 revenue totaled $27.5 million, representing year over year growth of 21% on a reported basis and 25% on a constant c

May 11, 2023 EX-99.2

Three months ended March 31,

EX-99.2 3 a2023q16-kreporttemplatest.htm EX-99.2 Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended March 31, Amounts in thousands of U.S. Dollars Note 2023 2022 Revenue 4 $ 27,457 $ 22,677 Cost of goods sold (9,843) (9,360) Gross profit 17,614 13,317 Selling expenses (11,995) (9,465) Administrative expenses (16,381) (14,3

May 11, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-402

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of principal

April 17, 2023 S-8

As filed with the Securities and Exchange Commission on April 17, 2023

As filed with the Securities and Exchange Commission on April 17, 2023 Registration No.

April 17, 2023 EX-99.2

First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan

Exhibit 99.2 First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan This First Amendment to Olink Holding AB (publ) Amended and Restated 2021 Incentive Award Plan (this “First Amendment”), made as of 14 March 2023, is made and adopted by Olink Holding AB (publ), a Swedish public limited liability company (the “Company”). Capitalized terms used but not otherwise d

April 17, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princip

April 17, 2023 EX-FILING FEES

Calculation of Filing Fee Table (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, quota value approx.

April 17, 2023 EX-99.1

Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023

Exhibit 99.1 Press release 17 April 2023 Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023 At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 17 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the no

April 13, 2023 EX-99.1

Olink to report first quarter 2023 financial results on May 11, 2023

Exhibit 99.1 Olink to report first quarter 2023 financial results on May 11, 2023 UPPSALA, Sweden, April 13, 2023 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2023 before the market open on Thursday, May 11, 2023. Company management will host a conference call to discuss these results at 8:00 am ET. Investors intereste

April 13, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princip

March 27, 2023 EX-99.2

Olink publishes 2022 annual report

Exhibit 99.2 Olink publishes 2022 annual report UPPSALA, Sweden, March 27, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2022 is now available on the Company’s website at https://investors.olink.com/. About Olink Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific communit

March 27, 2023 EX-13.2

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.2 Certification by the Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report on Form 20-F of Olink Holding AB (publ) (the “Company”) for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Oskar H

March 27, 2023 EX-99.1

The Board of Directors and the CEO of Olink Holding AB (publ) Corporate identity number 559189-7755 submit the following Annual report and consolidated financial statements for the financial year 1 January – 31 December 2022

Exhibit 99.1 The Board of Directors and the CEO of Olink Holding AB (publ) Corporate identity number 559189-7755 submit the following Annual report and consolidated financial statements for the financial year 1 January – 31 December 2022 Financial statements Olink Holding AB (publ) 559189-7755 Directors’ report 2 Consolidated statement of income and other comprehensive income for the year ended De

March 27, 2023 EX-4.10

First Amendment to Lease Agreement, dated as of October 20, 2021, by and between JC/SMP Waltham Owner, LLC. and Olink Proteomics AB.

a410firstamendmenttoleas DocuSign Envelope ID: A6CF8830·1AE6-499B-9E69-01854735E629 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY -HAS BEEN EXCLUDED PURSUANT TO THE INSTRUCTIONS TO FORM 20- F AND SEC RULES AND REGULA TIO NS.

March 27, 2023 EX-13.1

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report on Form 20-F of Olink Holding AB (publ) (the “Company”) for the year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Jon Hei

March 27, 2023 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

March 27, 2023 EX-2.5

Description of Securities

EX-2.5 2 a25descriptionofsecuriti.htm EX-2.5 Exhibit 2.5 Description of Securities DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Introduction Set forth below is a summary of certain information concerning Olink Holding AB (publ)'s (“us,” “our,” “we” or the “Company”) share capital as well as a description of certain provisions of our articles of association and relevant provisions of th

March 27, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princip

March 27, 2023 EX-12.1

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jon Heimer, certify that: 1.I have reviewed this annual report on Form 20-F of Olink Holding AB (publ); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or

March 27, 2023 EX-4.8

English summary of Lease Agreement, dated May 12, 2021, by and between Uppsala Kvarngärdet 27:2 AB and Olink Proteomics AB.

a48englishsummaryoflease English Summary Lease Agreement 54304-2031 Exhibit 4.8 The Lease Agreement (hereinafter referred to as the “Lease”) was entered into on 2021-05-12 by and between: I. Uppsala Kvarngärdet 27:2 AB (559226-7651) a limited partnership company with an address at c/o Bonnier Fastigheter AB Box 3167 103 63 Stockholm (“Landlord”) and II. Olink Proteomics AB, Dag Hammarskjölds väg 5

March 27, 2023 EX-4.1

Amended and Restated OEM Supply and License Agreement, dated as of December 1, 2022, by and between Bio-Techne Corp. and Olink Proteomics AB

a41olinksupplyandlicense Exhibit 4.1 /s/ Jon Heimer CEO

March 27, 2023 EX-4.9

Lease Agreement, dated April 1, 2021, by and between JC/SMP Waltham Owner, LLC. and Olink Proteomics AB.

a49leaseagreementdatedap DocuSign Envelope ID: B8B127E0-0F36-4A12-AAC3-CA946FB1D5F4 1 LEASE By and Between JC/SMP WALTHAM OWNER, LLC, (“Landlord”) And OLINK PROTEOMICS INC.

March 27, 2023 EX-15.1

Consent of Independent Registered Public Accounting Firm.

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: a.Registration Statement (Form S-8 No. 333-254844) b.Registration Statement (Form S-8 No. 333-264181) c.Registration Statement (Form F-3 No. 333-269285) of our report dated March 27, 2023, with respect to the consolidated financial statements

March 27, 2023 EX-12.2

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Oskar Hjelm, certify that: 1.I have reviewed this annual report on Form 20-F of Olink Holding AB (publ); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact o

March 27, 2023 EX-15.3

Consent of Öhrlings PricewaterhouseCoopers AB, independent registered public accounting firm.

Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-269285) and Form S-8 (Nos. 333-264181 and 333-254844) of Olink Holding AB (publ) of our report dated March 17, 2022 relating to the financial statements which appears in this Form 20-F. /s/ Öhrlings PricewaterhouseCoopers AB S

March 21, 2023 EX-99.1

Bruno Rossi joins Olink as Chief Commercial Officer

Exhibit 99.1 Bruno Rossi joins Olink as Chief Commercial Officer UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company’s global commercial organization including Sales, Market

March 21, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princip

March 15, 2023 EX-99.1

Total number of stock options/RSUs within the category

Exhibit 99.1 This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. Notice to attend the Annual General Meeting of Olink Holding AB (publ) The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be he

March 15, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princip

February 21, 2023 EX-99.1

Three months ended December 31

Exhibit 99.1 Olink reports fourth quarter and full year 2022 financial results UPPSALA, Sweden, February 21, 2023 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2022. Highlights •Fourth quarter revenue totaled $57.9 million, representing year over year growth of 33% on a repo

February 21, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of prin

February 21, 2023 EX-99.2

4Q 2022 earnings February 21, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Exhibit 99.2 Disclaimer This presentation may contain certain forward-looking statements and opinions. F

olk4q22xdeck 4Q 2022 earnings February 21, 2023 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Exhibit 99.

February 14, 2023 SC 13G/A

OLK / Olink Holding AB (publ) / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 olk13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) OLINK HOLDING AB - ADR (Name of Issuer) ADR (Title of Class of Securities) 680710100 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant t

January 23, 2023 EX-99.1

Olink Holding AB (publ) launches public offering of American Depositary Shares

EX-99.1 4 tm233507d10ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Olink Holding AB (publ) launches public offering of American Depositary Shares Uppsala, Sweden – January 18, 2023 – Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the launch of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ADSs”), consist

January 23, 2023 EX-1.1

Underwriting Agreement, dated as of January 18, 2023, by and between Olink Holding AB (publ) and Goldman Sachs Bank Europe SE and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein.

EX-1.1 2 tm233507d10ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version Olink Holding AB (publ) 5,831,028 American Depositary Shares representing 5,831,028 Common Shares, quota value SEK 2.431906612470569 per share Underwriting Agreement January 18, 2023 Goldman Sachs Bank Europe SE J.P. Morgan Securities LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule

January 23, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-40277

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Translation of registrant’s name into English) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of principal executiv

January 23, 2023 EX-99.2

Olink Holding AB (publ) announces pricing of public offering of American Depositary Shares

Exhibit 99.2 Olink Holding AB (publ) announces pricing of public offering of American Depositary Shares Uppsala, Sweden – January 18, 2023 – Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ADSs”), consisting of 4,250,000 ADSs offered by

January 20, 2023 EX-FILING FEES

Calculation of Filing Fee Tables (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424B5 (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Share, quota value approx.

January 20, 2023 424B5

5,831,028 American Depositary Shares Representing 5,831,028 Common Shares

424B5 1 tm233507-8424b5.htm 424B5 TABLE OF CONTENTS   Filed Pursuant to Rule 424(b)(5)  Registration No. 333-269285 PROSPECTUS SUPPLEMENT (To prospectus dated January 18, 2023) 5,831,028 American Depositary Shares Representing 5,831,028 Common Shares Olink Holding AB (publ) is offering 4,250,000 American Depositary Shares, or ADSs to be sold in the offering. The selling shareholders identified in

January 18, 2023 424B5

Subject to completion, dated January 18, 2023

424B5 1 tm233507-5424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities, and are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sa

January 18, 2023 F-3ASR

Form F-3ASR (File No. 333- 269285)

F-3ASR 1 tm233507-1f3asr.htm F-3ASR TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 18, 2023. Registration Statement No. 333-        UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Olink Holding AB (publ) (Exact name of registrant as specified in its charter) Not Applicable (T

January 18, 2023 EX-4.8

Form of Subordinated Indenture.

Exhibit 4.8 OLINK HOLDING AB (PUBL) FORM OF SUBORDINATED INDENTURE Dated as of [  ], 20[  ] [  ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 6 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Se

January 18, 2023 EX-FILING FEES

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM F-3 (Form Type) Olink Holding AB (publ) (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Share, quota value approx.

January 18, 2023 EX-4.7

Form of Senior Indenture.

Exhibit 4.7 OLINK HOLDING AB (PUBL) FORM OF SENIOR INDENTURE Dated as of [ ], 20[ ] [ ] Trustee Table of Contents Page Article I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 6 Article II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Se

January 11, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princ

January 11, 2023 EX-99.1

Olink Proteomics Jon Heimer, CEO JP Morgan Healthcare Conference January 11, 2023 San Francisco, CA Exhibit 99.1 Important notice This presentation may contain certain forward-looking statements and opinions. Forward-looking statements are statements

EX-99.1 2 olkjpmorganpresentation2.htm EX-99.1 Olink Proteomics Jon Heimer, CEO JP Morgan Healthcare Conference January 11, 2023 San Francisco, CA Exhibit 99.1 Important notice This presentation may contain certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the f

January 9, 2023 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001

6-K 1 cover6kxjanuaryx2023xforx.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-

January 9, 2023 EX-99.1

Olink announces preliminary unaudited revenue for the fourth quarter and full year 2022 and provides outlook for 2023

Exhibit 99.1 Olink announces preliminary unaudited revenue for the fourth quarter and full year 2022 and provides outlook for 2023 UPPSALA, Sweden, January 09, 2023 - Olink Holding AB (publ) (“Olink” or the “Company”) (Nasdaq: OLK), today announced preliminary unaudited revenue for the fourth quarter and year ended December 31, 2022, and additional selected unaudited performance metrics. Full year

December 29, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of prin

December 29, 2022 EX-99.1

Olink to participate in the 41

EX-99.1 2 olkjpm23x6kxpr.htm EX-99.1 Exhibit 99.1 Olink to participate in the 41st Annual JP Morgan Healthcare Conference UPPSALA, Sweden, December 29, 2022 - Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 41st Annual JP Morgan Healthcare Conference. Company management will present on Wednesday, January 11th, 2023 at 7:30 am PT. A live and archived webcas

November 10, 2022 EX-99.1

1 Olink press release I Third quarter 2022 report Exhibit 99.1 Olink reports third quarter 2022 financial results UPPSALA, Sweden, November 10, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited fin

1 Olink press release I Third quarter 2022 report Exhibit 99.1 Olink reports third quarter 2022 financial results UPPSALA, Sweden, November 10, 2022 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter of 2022. Highlights ? Third quarter 2022 revenue totaled $31.8 million, represenWng year over year growth of 59% o

November 10, 2022 EX-99.3

3Q 2022 earnings November 10, 2022 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Disclaimer This presentation may contain certain forward-looking statements and opinions. Forward-lookin

3Q 2022 earnings November 10, 2022 Olink Proteomics Vision Enable understanding of real-time human biology Mission Accelerate proteomics together Disclaimer This presentation may contain certain forward-looking statements and opinions.

November 10, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 00

6-K 1 cover6kxtoxbexaddedxtox6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE

November 10, 2022 EX-99.2

Three months ended September 30,

Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended September 30, Nine months ended September 30, Amounts in thousands of U.S. Dollars Note 2022 2021 2022 2021 Revenue 4 $ 31,772 $ 19,974 $ 81,963 $ 51,290 Cost of goods sold (10,785) (7,565) (30,589) (18,384) Gross profit 20,987 12,409 51,374 32,906 Selling expenses (11,240

November 1, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of prin

November 1, 2022 EX-99.1

Olink to participate in November investor events

Exhibit 99.1 Olink to participate in November investor events UPPSALA, Sweden, November 01, 2022 - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: ? Olink Investor Day 2022 Monday, November 14th at 11:00 am ET ? Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Thursday, November 17

October 13, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001

6-K 1 tm2227952d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83

October 13, 2022 EX-99.1

Olink to report third quarter 2022 financial results on November 10, 2022

Exhibit 99.1 Olink to report third quarter 2022 financial results on November 10, 2022 UPPSALA, Sweden, October 13, 2022 - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK) today announced it will release financial results for the third quarter of 2022 before the market open on Thursday, November 10, 2022. Company management will host a conference call to discuss these results at 8:00 am ET. Investo

August 31, 2022 EX-99.1

Olink strengthens management team for continued leadership in the modern proteomics era

Exhibit 99.1 Olink strengthens management team for continued leadership in the modern proteomics era UPPSALA, Sweden, August 31, 2022 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK) today announced several appointments in its leadership structure. Olink Chief Commercial Officer (CCO) Carl Raimond will be appointed President, effective upon the hiring of a new CCO, which is expec

August 31, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princi

August 30, 2022 EX-99.1

Olink to participate in September investor conferences

Exhibit 99.1 Olink to participate in September investor conferences UPPSALA, Sweden, August 30, 2022 - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK), today announced that Company management will participate in the following investor conferences: ? Goldman Sachs Medtech and Healthcare Services Conference Wednesday, September 7th at 6:30 am ET ? Morgan Stanley Healthcare Conference Monday, Septemb

August 30, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princi

August 11, 2022 EX-99.2

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND JUNE 30, 2021 (UNAUDITED)

Exhibit 99.2 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED) Three months ended June 30, Six months ended June 30, Amounts in thousands of U.S. Dollars Note 2022 2021 2022 2021 Revenue 4 $ 27,514 $ 17,688 $ 50,191 $ 31,316 Cost of goods sold (10,444 ) (5,823 ) (19,804 ) (10,819 ) Gross profit 17,070 11,865 30,387 20,497 Selling expenses (10,588 ) (6,9

August 11, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of princi

August 11, 2022 EX-99.3

August 11, 2022 Olink Proteomics Vision Enable understanding of real - time human biology Mission Accelerate proteomics together

Exhibit 99.3 August 11, 2022 Olink Proteomics Vision Enable understanding of real - time human biology Mission Accelerate proteomics together Disclaimer This presentation may contain certain forward - looking statements and opinions . Forward - looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for exa

August 11, 2022 EX-99.1

As of June 30,

Exhibit 99.1 Olink reports second quarter 2022 financial results UPPSALA, Sweden, August 11, 2022 (GLOBE NEWSWIRE) - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK) today announced its unaudited financial results for the second quarter of 2022. Highlights ? Second quarter 2022 revenue totaled $27.5 million, representing year over year growth of 56% on a reported basis and 62% on a constant currenc

July 14, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Uppsala, Sweden (Address of principa

July 14, 2022 EX-99.1

Olink to report second quarter 2022 financial results on August 11, 2022

Exhibit 99.1 Olink to report second quarter 2022 financial results on August 11, 2022 UPPSALA, Sweden, July 14, 2022 - Olink Holding AB (publ) (?Olink?) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2022 before the market open on Thursday, August 11, 2022. Company management will host a conference call to discuss these results at 8:00 am ET. Investors in

June 1, 2022 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40

6-K 1 tm2217296d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40277 OLINK HOLDING AB (PUBL) (Exact Name of Registrant as Specified in its Charter) Uppsala Science Park SE-751 83 Upp

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista